Latanoprost-Induced Side Effects and Potential Mechanisms

References

• Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: Structures, properties, and functions. Physiol. Rev. 1999; 79: 1193–1226
   PubMed Web of Science ®Google Scholar
• Pierce K. L., Regan J. W. Prostanoid receptor heterogeneity through alternative mRNA splicing. Life Sci. 1998; 62: 1479–1483
   PubMed Web of Science ®Google Scholar
• Coleman R. A., Smith W L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 1994; 46: 205–229
   PubMed Web of Science ®Google Scholar
• Woodward D. F., Chan M. F., Burke J. A., Cheng-Bennett A., Chen G., Fairbairn C. E., Gac T., Garst M. E., Gluchowski C., Kaplan L. J. Studies on the ocular hypotensive effects of prostaglandin F2 alpha ester prodrugs and receptor selective prostaglandin analogs. J. Ocul. Pharmacol. 1994; 10: 177–193
   PubMedGoogle Scholar
• Bito L. Z., Camras C. B., Gum G. G., Resul B. The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals. Prog. Clin. Biol. Res. 1989; 312: 349–368
   PubMedGoogle Scholar
• Camras C. B., Aim A. Initial clinical studies with prostaglandins and their analogues. Surv. Ophthalmol. 1997; 41: S61–S68
   PubMed Web of Science ®Google Scholar
• Dijkstra B. G., Schneemann A., Hoyng P. F. Flow after prostaglandin El is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol. Vis. Sci. 1999; 40: 2622–2626
   PubMed Web of Science ®Google Scholar
• Yousufzai S. Y., Ye Z., Abdel-Latif A. A. Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp. Eye Res. 1996; 63: 305–310
   PubMed Web of Science ®Google Scholar
• Karlsson M., Selen G., Stjernschantz J., Resul B. Receptor profile of PhXA41, a new phenyl substituted prostaglandin ester. Exp. Eye Res. 1992; 55: 50
   Google Scholar
• Ocklind A., Lake S., Wentzel P., Nister M., Stjernschantz J. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest. Ophthalmol. Vis. Sci. 1996; 37: 716–726
   PubMed Web of Science ®Google Scholar
• Lindsey J. D., Kashiwagi K., Kashiwagi F., Weinreb R. N. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow. Surv. Ophthalmol. 1997; 41: S53–S59
   PubMed Web of Science ®Google Scholar
• Lutjen-Drecoll E., Taram E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp. Eye Res. 1988; 47: 761–769
   PubMed Web of Science ®Google Scholar
• Crawford K., Kaufman P. L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch. Ophthalmol. 1987; 105: 1112–1116
   PubMed Web of Science ®Google Scholar
• Anthony T. L., Pierce K. L., Stamer W. D., Regan J. W. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 1998; 39: 315–321
   PubMed Web of Science ®Google Scholar
• Bradley J. M., Anderssohn A. M., Colvis C. M., Parshley D. E., Zhu X. H., Ruddat M. S., Samples J. R., Acott T. S. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-lbeta and TNFalpha. Invest. Ophthalmol. Vis. Sci. 2000; 41: 422–430
   PubMed Web of Science ®Google Scholar
• Boie Y., Sawyer N., Slipetz D. M., Metiers K. M., Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 1995; 270: 18910–18916
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P., Geoghegan T. E., Patil R. V., Bhattacherjee P., Paterson C. A. Detection of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle cells. Biochem. Pharmacol. 1997; 53: 1249–1255
   PubMed Web of Science ®Google Scholar
• Gil D. W., Bogardus A. M., Bailey T. J., Donello J. E., Fairbairn C. E., Kedzie K. M., Pierce K., Woldemussie E., Woodward D. F., Regan J. W., Human E P. prostaglandin receptor: Cloning and localization of four variants in anterior segment. Invest. Ophthalmol. Vis. Set 1994; 35: 1983
   Web of Science ®Google Scholar
• Chen Z., Prasad S., Cynader M. Localisation of thromboxane A2 receptors and the corresponding mRNAs in human eye tissue [see comments]. Br. J. Ophthalmol. 1994; 78: 921–926
   PubMed Web of Science ®Google Scholar
• Woodward D. F., Regan J. W., Lake S., Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv. Ophthalmol. 1997; 41: S15–S21
   PubMed Web of Science ®Google Scholar
• Tsai S. J., Anderson L. E., Juengel J., Niswender G. D., Wiltbank M. C. Regulation of prostaglandin F2 alpha and E receptor mRNA by prostaglandin F2 alpha in ovine corpora lutea. J. Reprod. Fertil. 1998; 114: 69–75
   PubMedGoogle Scholar
• Brodt-Eppley J., Myatt L. Prostaglandin receptors in lower segment myometrium during gestation and labor. Obstet. Gynecol. 1999; 93: 89–93
   PubMed Web of Science ®Google Scholar
• Watanabe Y., Tokumoto H., Yamashita A., Narumiya S., Mizuno N., Hayaishi O. Specific bindings of prostaglandin D2, E2 and F2 alpha in postmortem human brain. Brain Res. 1985; 342: 110–116
   PubMed Web of Science ®Google Scholar
• Sugimoto Y., Hasumoto K., Namba T., Irie A., Katsuyama M., Negishi M., Kakizuka A., Narumiya S., Ichikawa A. Cloning and expression of a cDNA for mouse prostaglandin F receptor. J. Biol. Chem. 1994; 269: 1356–1360
   PubMed Web of Science ®Google Scholar
• Chen J., Champa-Rodriguez M. L., Woodward D. F. Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein. Br. J. Pharmacol. 1995; 116: 3035–3041
   PubMed Web of Science ®Google Scholar
• Sugimoto Y., Yamasaki A., Segi E., Tsuboi K., Aze Y., Nishimura T., Oida H., Yoshida N., Tanaka T., Katsuyama M., Hasumoto K., Murata T., Hirata M., Ushikubi F., Negishi M., Ichikawa A., Narumiya S. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997; 277: 681–683
   PubMed Web of Science ®Google Scholar
• Chen J., Woodward D. F., Yuan Y. D., Marshall K., Senior J. Prostanoid-induced contraction of the rabbit isolated uterus is mediated by FP receptors. Prostaglandins Lipid Mediators 1998; 55: 387–394
   PubMed Web of Science ®Google Scholar
• Eglen R. M., Whiting R. L. The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets. Br. J. Pharmacol. 1988; 94: 591–601
   PubMed Web of Science ®Google Scholar
• Coleman R. A., Sheldrick R. L. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br. J. Pharmacol. 1989; 96: 688–692
   PubMed Web of Science ®Google Scholar
• Mosby's GenRx—The Complete Reference for Generic and Brand Drugs. St Louis, Mosby 1999; 11, 352–353
   Google Scholar
• Wistrand P. J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Ophthalmol. 1997; 41: S129–S138
   PubMed Web of Science ®Google Scholar
• Selen G., Stjernschantz J., Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv. Ophthalmol. 1997; 41: S125–S128
   PubMed Web of Science ®Google Scholar
• Imesch P. D., Wallow I. H., Albert D. M. The color of the human eye: A review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv. Ophthalmol. 1997; 41: S117–S123
   PubMed Web of Science ®Google Scholar
• Grierson I., Lee W. R., Albert D. M. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch. Ophthalmol. 1999; 117: 394–396
   PubMed Web of Science ®Google Scholar
• Lindquist N. G., Larsson B. S., Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp. Eye Res. 1999; 68: 431–436
   PubMed Web of Science ®Google Scholar
• Drago F., Marino A., LaManna C. alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp. Eye Res. 1999; 68: 85–90
   PubMed Web of Science ®Google Scholar
• Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch. Ophthalmol. 1997; 115: 1206–1208
   PubMed Web of Science ®Google Scholar
• Reynolds A., Murray P. I., Colloby P. S. Darkening of eyelashes in a patient treated with latanoprost. Eye; 1998; 12: 741–743
   PubMed Web of Science ®Google Scholar
• Johnstone M. A. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am. J. Ophthalmol. 1997; 124: 544–547
   PubMed Web of Science ®Google Scholar
• Aim A., Camras C. B., Watson P. G. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv. Ophthalmol. 1997; 41: S105–S110
   PubMed Web of Science ®Google Scholar
• Astin M. Effects of prostaglandin E2, F2alpha, and latanoprost acid on isolated ocular blood vessels in vitro. J. Ocul. Pharmacol. Ther. 1998; 14: 119–128
   PubMed Web of Science ®Google Scholar
• Astin M., Stjernschantz J. Mechanism of prostaglandin E2-, F2alpha- and latanoprost acid-induced relaxation of submental veins. Eur. J. Pharmacol. 1997; 340: 195–201
   PubMed Web of Science ®Google Scholar
• Astin M., Stjernschantz J. Mediation of prostaglandin F2 alpha-induced ocular surface hyperemia by sensory nerves in rabbits. Curr. Eye Res. 1997; 16: 886–890
   PubMed Web of Science ®Google Scholar
• Astin M., Stjernschantz J., Selen G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp. Eye Res. 1994; 59: 401–407
   PubMed Web of Science ®Google Scholar
• Warwar R. E., Bullock J. D., Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105: 263–268
   PubMed Web of Science ®Google Scholar
• Wardrop D. R., Wishart P. K. Latanoprost and cystoid macular oedema in a pseudophake. Br. J. Ophthalmol. 1998; 82: 843–844
   PubMed Web of Science ®Google Scholar
• Rowe J. A., Hattenhauer M. G., Herman D. C. Adverse side effects associated with latanoprost. Am. J. Ophthalmol. 1997; 124: 684–685
   Google Scholar
• Moroi S. E., Gottfredsdottir M. S., Schteingart M. T., Elner S. G., Lee C. M., Schertzer R. M., Abrams G. W., Johnson M. W. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999; 106: 1024–1029
   PubMed Web of Science ®Google Scholar
• Miyake K., Ota I., Maekubo K., Ichihashi S., Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch. Ophthalmol. 1999; 117(1)34–40
   PubMed Web of Science ®Google Scholar
• Ayyala R. S., Cruz D. A., Margo C. E., Harman L. E., Pautler S. E., Misch D. M., Mines J. A., Richards D W. Cystoid macular edema associated with latanoprost in aphakic and pseu-dophakic eyes. Am. J. Ophthalmol. 1998; 126: 602–604
   PubMed Web of Science ®Google Scholar
• Callanan D., Fellman R. L., Savage J. A. Latanoprost-associated cystoid macular edema. Am. J. Ophthalmol. 1998; 126: 134–135
   PubMed Web of Science ®Google Scholar
• Heier J. S., Steinert R. F., Frederick A. R., Jr. Cystoid macular edema associated with latanoprost use. Arch. Ophthalmol. 1998; 116: 680–682
   PubMed Web of Science ®Google Scholar
• Avakian A., Renier S. A., Butler P. J. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch. Ophthalmol. 1998; 116: 679–680
   PubMed Web of Science ®Google Scholar
• Gaddie I. B., Bennett D. W. Cystoid macular edema associated with the use of latanoprost. J. Am. Optom. Assoc. 1998; 69: 122–128
   PubMedGoogle Scholar
• Wand M., Gaudio A., Shields B. Cystoid macular edema and latanoprost: A prospective study. American Glaucoma Society Tenth Annual Meeting. 2000, 38
   Google Scholar
• Toris C. B., Camras C. B., Yablonski M. E., Brubaker R. F. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv. Ophthalmol 1997; 41: S69–S75
   PubMed Web of Science ®Google Scholar
• Fechtner R. D., Khouri A. S., Zimmerman T. J., Bullock J., Feldman R., Kulkarni P., Michael A. J., Realini T., Warwar R. Anterior uveitis associated with latanoprost. Am. J. Ophthalmol. 1998; 126: 37–41
   PubMed Web of Science ®Google Scholar
• Wand M., Gilbert C. M., Liesegang T. J. Latanoprost and herpes simplex keratitis. Am. J. Ophthalmol. 1999; 127: 602–604
   PubMed Web of Science ®Google Scholar
• Harbour D. A., Hill T. J., Biyth W. A. Prostaglandins enhance intercellular adhesion of Veto cells infected with herpes simplex virus. J. Gen. Virol. 1983; 64: 507–512
   PubMed Web of Science ®Google Scholar
• Harbour D. A., Blyth W. A., Hill T. J. Prostaglandins enhance spread of herpes simplex virus in cell cultures. J. Gen. Virol. 1978; 41: 87–95
   PubMed Web of Science ®Google Scholar
• Kaufman H. E., Varnell E. D., Thompson H. W. Latanoprost increases the severity and recurrence ofherpetic keratitis in the rabbit [comment]. Am. J, Ophthalmol. 1999; 127: 531–536
   PubMed Web of Science ®Google Scholar
• Sudesh S., Cohen E. J., Rapuano C. J., Wilson R. P. Corneal toxicity associated with latanoprost. Arch. Ophthalmol. 1999; 117: 539–540
   PubMed Web of Science ®Google Scholar
• Krohn J., Hove V K. Iris cyst associated with topical administration of latanoprost. Am. Ophthalmol J. 1999; 127: 91–93
   PubMed Web of Science ®Google Scholar
• Ness T., Funk J. Increase of intraocular pressure after topical administration of prostaglandin analogs. Arch. Ophthalmol. 1999; 117: 1646–1647
   PubMed Web of Science ®Google Scholar
• Peak A. S, Sutton B. M. Systemic adverse effects associated with topically applied latanoprost. Ann. Pharmacother. 1998; 32: 504–505
   PubMed Web of Science ®Google Scholar
• Hayashi S., Park M. K., Kuehl T. J. Relaxant and contractile responses to prostaglandins in premature, newborn and adult baboon cerebral arteries. J. Pharmacol. Exp. Ther. 1985; 233: 628–635
   PubMed Web of Science ®Google Scholar
• Kawai Y., Ohhashi T. Prostaglandin F2 alpha-induced endothelium-dependent relaxation in isolated monkey cerebral arteries. Am. J. Physiol 1991; 260: H1538–H1543
   PubMed Web of Science ®Google Scholar
• Toda N., Inoue S., Okamura T., Okunishi H. Mechanism underlying relaxations caused by prostaglandins and thromboxane A2 analog in isolated dog arteries. J. Cardiovasc. Pharmacol. 1988; 11: 354–362
   PubMed Web of Science ®Google Scholar
• Watanabe T., Waga I., Honda Z., Kurokawa K., Shimizu T. Prostaglandin F2 alpha stimulates formation of p21ras-GTP complex and mitogen-activated protein kinase in NIH-3T3 cells via Gq-protein-coupled pathway. J. Biol. Chem. 1995; 270: 8984–8990
   PubMed Web of Science ®Google Scholar
• Jimenez D. A., Otto A. M., Lindgren J. A., Hammarstrom S. The stimulation of the initiation of DNA synthesis and cell division in Swiss mouse 3T3 cells by prostaglandin F2 alpha requires specific functional groups in the molecule. J. Biol. Chem. 1983; 258: 8774–8780
   PubMed Web of Science ®Google Scholar
• Quarles L. D., Haupt D. M., Davidai G., Middleton J. P. Prostaglandin F2 alpha-induced mitogenesis in MC3T3-E1 osteoblasts: Role of protein kinase-C-mediated tyrosine phosphorylation. Endocrinology 1993; 132: 1505–1513
   PubMed Web of Science ®Google Scholar
• Serrero G., Lepak N. M. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem. Biophys. Res. Commun. 1997; 233: 200–202
   PubMed Web of Science ®Google Scholar
• Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature 1978; 272: 634–636
   PubMed Web of Science ®Google Scholar
• Aim A., Stjemschantz J. Effects on intraocular pressure and side effects of 0.005% latano-prost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latano-prost Study Group. Ophthalmology 1995; 102: 1743–1752
   PubMed Web of Science ®Google Scholar
• Watson P., Stjemschantz J. A six-month, randomized, double-masked study comparing lata-noprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996; 103: 126–137
   PubMed Web of Science ®Google Scholar
• Camras C. B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103: 138–147
   PubMed Web of Science ®Google Scholar
• Pappas R. M., Pusin S., Higginbotham E. J. Evidence of early change in iris color with latanoprost use. Arch. Ophthalmol. 1998; 116: 1115–1116
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J. Glaucoma. 1997; 6: 430–432
   PubMed Web of Science ®Google Scholar
• Bito L. Z. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv, Ophthalmol. 1997; 41: S1–S14
   PubMed Web of Science ®Google Scholar
• Prescott S., White R. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 1996; 87: 783–786
   PubMed Web of Science ®Google Scholar
• Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803–809
   PubMed Web of Science ®Google Scholar
• Jacoby R. F., Marshall D. J., Newton M. A., Novakovic K., Tutsch K., Cole C. E., Lubet R. A., Kelloff G. J., Verma A., Moser A. R., Dove W. F. Chemoprevention of spontaneous intestinal adenomas in the Ape Min mouse model by the nonsteroidal anti-inflammatory drug piroxi-cam. Cancer Res. 1996; 56: 710–714
   PubMed Web of Science ®Google Scholar
• Tsujii M., DuBois R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501
   PubMed Web of Science ®Google Scholar
• Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxy-genase-2 in human breast cancer. J. Natl. Cancer Inst. 1998; 90: 455–460
   PubMed Web of Science ®Google Scholar
• Liu X. H., Rose D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996; 56: 5125–5127
   PubMed Web of Science ®Google Scholar
• Buckman S. Y., Gresham A, Hale P., Hruza G., Anast J., Masferrer J., Pentland A. P. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis 1998; 19: 723–729
   PubMed Web of Science ®Google Scholar
• Lark K. K., Pasha A. S., Yan X., Edward D. P. The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts. J. Glaucoma 1999; 8: 72–76
   PubMed Web of Science ®Google Scholar
• Hu D. N., Stjemschantz J., McCormick S. A. Effect of prostaglandins A(2), E(1), F(2 alpha) and latanoprost on cultured human iridal melanocytes. Exp. Eye Res. 2000; 70: 113–120
   PubMed Web of Science ®Google Scholar
• Goin M., Pignataro O., Jimenez D. A. Early cell cycle diacylglycerol (DAG) content and protein kinase C (PKC) activity enhancement potentiates prostaglandin F2 alpha (PGF2 alpha) induced mitogenesis in Swiss 3T3 cells. FEBS Lett. 1993; 316: 68–72
   PubMed Web of Science ®Google Scholar
• Stjemschantz J., Selen G., Astin M., Karlsson M., Resul B. Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye. Arch. Ophthalmol. 1999; 117: 1363–1367
   PubMed Web of Science ®Google Scholar
• Stjemschantz J., Nilsson S. F., Astin M. Vasodynamic and angiogenic effects of eicosanoids in the eye. The Ocular Effects of Prostaglandins and Other Eicosanoids, L. Z. Bito. Alan R. Liss, Inc., New York 1989; 155–170
   Google Scholar
• Arner M., Uski T., Hogestatt E. D. Endothelium dependence of prostanoid-induced relaxation in human hand veins. Acta Physiol. Scand. 1994; 150: 267–272
   PubMedGoogle Scholar
• Kimura T., Okamura T., Yoshida Y., Toda N. Relaxant responses to prostaglandin F2 alpha and E2 of isolated human uterine arteries. J. Cardiovasc. Pharmacol. 1995; 26: 333–338
   PubMed Web of Science ®Google Scholar
• Nielsen P. J., Nyborg N. C. Contractile and relaxing effects of arachidonic acid derivatives on isolated bovine retinal resistance arteries. Exp. Eye Res. 1990; 50: 305–311
   PubMed Web of Science ®Google Scholar
• Ohkubo H., Chiba S. Vascular reactivities of simian ophthalmic and ciliary arteries. Curr. Eye Res. 1987; 6: 1197–1203
   PubMed Web of Science ®Google Scholar
• Goodwin D. C., Landino L. M., Marnett L. J. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J. 1999; 13: 1121–1136
   PubMed Web of Science ®Google Scholar
• Salvemini D., Misko T. P., Masferrer J. L., Seibert K., Currie M. G., Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Set USA 1993; 90: 7240–7244
   PubMed Web of Science ®Google Scholar
• Swierkosz T. A., Mitchell J. A., Warner T. D., Botting R. M., Vane J. R. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br. J. Pharmacol. 1995; 114: 1335–1342
   PubMed Web of Science ®Google Scholar
• Corbett J. A., Kwon G., Turk J., McDaniel M. L. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: Activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32: 13767–13770
   PubMed Web of Science ®Google Scholar
• Davidge S. T., Baker P. N., Laughlin M. K., Roberts J. M. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ. Res. 1995; 77: 274–283
   PubMed Web of Science ®Google Scholar
• Stadler J., Harbrecht B. G., DiSilvio M., Curran R. D., Jordan M. L., Simmons R. L., Billiar T. R. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J. Leukocyte Biol. 1993; 53: 165–172
   PubMed Web of Science ®Google Scholar
• Habib A., Bernard C., Lebret M., Creminon C., Esposito B., Tedgui A., Maclouf J. Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages. J. Immunol. 1997; 158: 3845–3851
   PubMed Web of Science ®Google Scholar
• Okamoto H., Ito O., Roman R. J., Hudetz A. G. Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia. Stroke 1998; 29: 1209–1218
   PubMed Web of Science ®Google Scholar
• Seong G. J., Lee H. K., Hong Y. J. Effects of 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow. Ophthalmologica 1999; 213: 355–359
   PubMed Web of Science ®Google Scholar
• Altuna J. C., Greenfield D. S., Wand M., Liebmann J. M., Taglia D. P., Kaufman P. L., Cioffi G. A., Lee D. A., Robin A. L., Crichton A., Costa V. P., Ritch R. Latanoprost in glaucoma associated with Sturge-Weber syndrome: Benefits and side-effects. J. Glaucoma 1999; 8: 199–203
   PubMed Web of Science ®Google Scholar
• Samples J. R. Glaucoma associated with elevated venous pressure. Current Ocular Therapy, 5th ed., F. W. Fraunfelder, F. H. Roy. W. B. Saunders, Philadelphia 2000; 471–472
   Google Scholar
• Irvine A. R. Cystoid maculopathy. Surv. Ophthalmol. 1976; 21: 1–17
   PubMedGoogle Scholar
• Chang A. A., Spaide R. F., Yannuzzi L. A. Postsurgical cystoid macular edema. Retina- Vitreous-Macula, 1st ed., D. R. Guyer, L. A. Yannuzzi, S. Chang, J. A. Shields, W. R. Green. W. B. Saunders, Philadelphia 1999; 238–255
   Google Scholar
• Jaffe N. S., Jaffe M. S., Jaffe G. F. Cystoid macular edema. Cataract Surgery and Its Complications, 7th ed. Mosby-Year Book, Inc., St. Louis 1997; 319–333
   Google Scholar
• Nikica G., Ljerka H. P., Jelena P., Metez-Soldo K., Mladen B. Cystoid macular edema in anterior chamber lens implantation following posterior capsule rupture. Doc. Ophthalmol. 1992; 81: 309–315
   PubMed Web of Science ®Google Scholar
• Kraff M. C., Sanders D. R., Jampol L. M., Lieberman H. L. Effect of primary capsulotomy with extracapsular surgery on the incidence of pseudophakic cystoid macular edema. Am. J. Ophthalmol. 1984; 98: 166–170
   PubMed Web of Science ®Google Scholar
• Protzman C. E., Woodward D. F. Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype. Invest. Ophthalmol. Vis. Sci. 1990; 31: 2463–2466
   PubMed Web of Science ®Google Scholar
• Miyake K., Mibu H., Horiguchi M., Shirasawa E. Inflammatory mediators in postoperative aphakic and pseudophakic baboon eyes. Arch. Ophthalmol. 1990; 108: 1764–1767
   PubMed Web of Science ®Google Scholar
• Camras C. B., Bhuyan K. C., Podos S. M., Bhuyan D. K., Master R. W. Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. II. Slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest. Ophthalmol. Vis. Sci. 1987; 28: 921–926
   PubMed Web of Science ®Google Scholar
• Hoyng P. F., Rulo A. H., Greve E. L., Astin M., Gjotterberg M. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv. Ophthalmol. 1997; 41: S83–S88
   PubMed Web of Science ®Google Scholar
• Camras C. B., Aim A., Watson P., Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103: 1916–1924
   PubMed Web of Science ®Google Scholar
• Mishima H. K., Masuda K., Kitazawa Y., Azuma I., Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study [see comments]. Arch. Ophthalmol. 1996; 114: 929–932
   PubMed Web of Science ®Google Scholar
• Kulkami P. S., Srinivasan B. D. Cyclooxygenase and lipoxygenase pathways in anterior uvea and conjunctiva. Prog. Clin. Biol. Res. 1989; 312: 39–52
   PubMedGoogle Scholar
• Eakins K. E., Whitelocke R. A., Bennett A., Martenet A. C. Prostaglandin-like activity in ocular inflammation. Br. Med. J. 1972; 3: 452–453
   PubMed Web of Science ®Google Scholar
• Linden C., Nuija E., Aim A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br. J. Ophthalmol. 1997; 81: 370–372
   PubMed Web of Science ®Google Scholar
• Lu R., Kanai N., Bao Y., Schuster V. L. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J. Clin. Invest. 1996; 98: 1142–1149
   PubMed Web of Science ®Google Scholar
• Chan B. S., Satriano J. A., Pucci M, Schuster V. L. Mechanism of prostaglandin E2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter “PGT,”. J. Biol. Chem. 1998; 273: 6689–6697
   PubMed Web of Science ®Google Scholar
• Schuster V. L., Lu R., Coca-Prados M. The prostaglandin transporter is widely expressed in ocular tissues. Surv. Ophthalmol 1997; 41: S41–S45
   PubMed Web of Science ®Google Scholar
• Cheng-Bennett A., Poyer J., Weinkam R. J., Woodward D. F. Lack of prostaglandin F2 alpha metabolism by human ocular tissues. Invest Ophthalmol. Vis. Sci. 1990; 31: 1389–1393
   PubMed Web of Science ®Google Scholar
• Bito L. Z., Wallenstein M. C. Transport of prostaglandins across the blood-brain and blood-aqueous barriers and the physiological significance of these absorptive transport processes. Exp. Eye Res. 1977; 25: 229–243, Suppl
   PubMed Web of Science ®Google Scholar
• Bito L. Z. The effects of experimental uveitis on anterior uveal prostaglandin transport and aqueous humor composition. Invest. Ophthalmol. 1974; 13: 959–966
   PubMedGoogle Scholar
• Birkle D. L., Sanitato J. J., Kaufman H. E., Bazan N. G. Arachidonic acid metabolism to eicosanoids in herpes virus-infected rabbit cornea. Invest. Ophthalmol. Vis. Sci. 1986; 27: 1443–1446
   PubMed Web of Science ®Google Scholar